Temple University and Thomas Jefferson University’s Center for Medical Cannabis Education & Research Announce Groundbreaking Collaboration and Cannabinoid Conference
Temple University, a national leader in substance abuse research, announced today a groundbreaking collaboration with Thomas Jefferson University’s Center for Medical Cannabis Education & Research (“CMCER”), the nation’s first comprehensive resource for expert-developed, unbiased information about the medical uses of marijuana and cannabinoid focused-therapies to be housed within a major US health sciences university.
With the recent signing of PA Act 16, which legalized the use of medical marijuana for the adjunct treatment of specific medical conditions within Pennsylvania, new opportunities to address critical regional and state-wide health concerns are likely to emerge. Together, the institutions seek to encourage research and education initiatives involving physicians and scientists working within each respective institution and elsewhere in the Commonwealth and the nation.
To help kickoff this collaboration, Temple’s Lewis Katz School of Medicine and its Center for Substance Abuse Research and CMCER will be co-presenting the 2016 Carolina Cannabinoid Collective Conference on October 28th-30th. Over 100 of the country’s leading cannabinoid researchers will gather in Philadelphia to address recent developments and discoveries. The Conference will feature as its keynote speakers Donald Abrams, MD, Chief of Hematology-Oncology at Zuckerberg San Francisco General Hospital, and a member of CMCER’s international Academic Steering Committee, and Yasmin Hurd, PhD, Professor of Psychiatry, Neuroscience and Pharmacology and Systems Therapeutics, and Director of the Center for Addictive Disorders at the Icahn School of Medicine at Mount Sinai.
Representing the leadership supporting this institutional collaboration, Larry R. Kaiser, M.D., FACS, Dean of the Lewis Katz School of Medicine at Temple University, stated: “This new collaboration brings together researchers who are truly among the best in the nation. Temple’s Center for Substance Abuse Research is one of 14 in the United States to be designated a Core Center of Excellence by the National Institute on Drug Abuse and includes experts in disciplines as diverse as pharmacology, microbiology, and immunology. Joining forces with CMCER multiplies the potential for producing important insights on the appropriate and safe therapeutic uses of medical cannabis.”
Echoing Dr. Kaiser’s sentiments, Michele Masucci, Ph.D., VP for Research at Temple University, stated: “We believe we can leverage our world-class research faculty, facilities and clinical expertise to advance knowledge related to medical marijuana in areas such as substance abuse, drug discovery and treatment of patients with chronic conditions. We see opportunities both in researching how cannabinoids relate to addiction, as well as how they can support therapeutic outcomes.”
Likewise, Thomas Jefferson University’s Charles V. Pollack, Jr., MA, M.D., FACEP, FAAEM, FESC, FAHA, FCPP, Director of CMCER, stated, “The Center is a resource for medical schools across the Commonwealth and across the nation. Our mission is to elevate the science underpinning medical cannabis, and in doing so improve the patient experience for those with chronic medical conditions that may be responsive to this therapy. We have an opportunity to develop a best-in-class approach to the medical use of marijuana in Pennsylvania, given the unique emphasis in PA Act 16 and from Governor Wolf’s office on supporting meaningful research as part of the ’business‘ of medical cannabis. This new collaboration between Temple University and TJU is emblematic of the CMCER’s resolve to meet its mission, and will demonstrate the benefit of collaboration among PA medical schools in further understanding best use of medical marijuana.”
For more information about the Carolina Cannabinoid Collective Conference, please visit www.CCCPHL2016.com.